Polymorphisms of Killer Ig-like Receptors and the Risk of Glioblastoma.

KIR Koreans glioblastoma immunogenetics polymorphism

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
19 Jul 2023
Historique:
received: 10 06 2023
revised: 08 07 2023
accepted: 18 07 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

The immune responses of natural killer (NK) cells against cancer cells vary by patient. Killer Ig-like receptors (KIRs), which are some of the major receptors involved in regulating NK cell activity for killing cancer cells, have significant genetic variation. Numerous studies have suggested a potential association between the genetic variation of KIR genes and the risk of development or prognosis of various cancer types. However, an association between genetic variations of KIR genes and glioblastoma (GB) remains uncertain. We sought to evaluate the association of genetic variations of KIRs and their ligand genes with the risk of GB development in Koreans. A case-control study was performed to identify the odds ratios (ORs) of KIR genes and Classes A, B, and, C of the human leukocyte antigen (HLA) for GB. The GB group was comprised of 77 patients with newly diagnosed IDH-wildtype GB at our institution, and the control group consisted of 200 healthy Korean volunteers. There was no significant difference in the frequency of KIR genes and KIR haplotypes between the GB and control groups. Genetic variations of KIR-2DL1, 3DL1, and 3DS1 with their ligand genes (HLA-C2, HLA-Bw4/6, and Bw4, respectively) had effects on the risk of GB in Korean patients. The frequency of KIR-2DL1 with HLA-C2 (OR 2.05, CI 1.19-3.52, This study suggests that genetic variations of KIRs and their ligand genes may affect GB development in the Korean population. Further investigations are needed to demonstrate the different immune responses for GB cells according to genetic variations of KIR genes and their ligand genes.

Identifiants

pubmed: 37510895
pii: jcm12144780
doi: 10.3390/jcm12144780
pmc: PMC10380963
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Exp Med. 1990 May 1;171(5):1509-26
pubmed: 1692080
Cell. 2022 Apr 28;185(9):1521-1538.e18
pubmed: 35447071
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Cancer Res. 2014 Jul 1;74(13):3466-76
pubmed: 24795429
Cancer Res. 2007 Apr 15;67(8):3540-4
pubmed: 17440061
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95
pubmed: 36196752
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Sci Rep. 2018 Apr 17;8(1):6104
pubmed: 29666399
Nat Rev Clin Oncol. 2021 Feb;18(2):85-100
pubmed: 32934330
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Hum Immunol. 2017 Oct;78(10):614-620
pubmed: 28734803
J Immunol. 1983 Oct;131(4):1789-96
pubmed: 6225799
PLoS One. 2021 Dec 9;16(12):e0260618
pubmed: 34882724
Sci Rep. 2022 Oct 14;12(1):17237
pubmed: 36241658
J Neuroimmunol. 2000 Jul 24;107(2):220-5
pubmed: 10854660
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
Cancer Res. 2011 Dec 15;71(24):7433-41
pubmed: 22006996
Blood. 2016 Dec 15;128(24):2819-2823
pubmed: 27760759
Neuro Oncol. 2023 Jan 5;25(1):123-134
pubmed: 35419607
Eur J Immunol. 2013 Oct;43(10):2756-64
pubmed: 23913266
Sci Transl Med. 2013 Oct 23;5(208):208ra145
pubmed: 24154599
Neuro Oncol. 2022 Nov 2;24(11):1935-1949
pubmed: 35511454
Blood. 2008 Aug 1;112(3):461-9
pubmed: 18650461
Neuro Oncol. 2015 Nov;17 Suppl 7:vii9-vii14
pubmed: 26516226
Cell Metab. 2016 Nov 8;24(5):657-671
pubmed: 27641098
Neuro Oncol. 2016 Feb;18(2):195-205
pubmed: 26323609
J Korean Med Sci. 2011 Nov;26(11):1483-8
pubmed: 22065905
J Neuropathol Exp Neurol. 2005 Jun;64(6):523-8
pubmed: 15977644
Neuro Oncol. 2011 Jun;13(6):591-9
pubmed: 21636707
Cancer Genomics Proteomics. 2022 Mar-Apr;19(2):151-162
pubmed: 35181585
Curr Treat Options Neurol. 2018 Apr 18;20(5):14
pubmed: 29666934
PLoS One. 2019 May 15;14(5):e0216941
pubmed: 31091281
Int J Surg. 2014;12(8):815-20
pubmed: 24998207
J Immunol. 1986 Jun 15;136(12):4480-6
pubmed: 3086432
EMBO Mol Med. 2022 Dec 7;14(12):e15343
pubmed: 36278433
Curr Top Microbiol Immunol. 2006;298:23-57
pubmed: 16329184
Blood. 2013 Apr 4;121(14):2678-88
pubmed: 23325834
Science. 2000 Oct 6;290(5489):84-9
pubmed: 11021804
Cell. 2020 Jun 25;181(7):1643-1660.e17
pubmed: 32470396
Cancers (Basel). 2018 Dec 18;10(12):
pubmed: 30567306
Nat Rev Neurol. 2022 Sep;18(9):515-529
pubmed: 35729337
Turk Neurosurg. 2019;29(4):570-575
pubmed: 30984996
Lab Invest. 2017 May;97(5):498-518
pubmed: 28287634
Biomedicines. 2023 Jan 22;11(2):
pubmed: 36830847
Cell Mol Immunol. 2019 May;16(5):430-441
pubmed: 30778167
Immunol Cell Biol. 2019 May;97(5):457-469
pubmed: 30575118
Front Immunol. 2020 Jul 31;11:1549
pubmed: 32903717
J Immunol. 2005 May 15;174(10):6540-5
pubmed: 15879158
J Immunol. 2002 May 1;168(9):4772-80
pubmed: 11971028
Cancer Res. 2006 Apr 1;66(7):3852-8
pubmed: 16585213
J Neurooncol. 2022 Mar;157(1):177-185
pubmed: 35175545
Nat Rev Immunol. 2013 Feb;13(2):133-44
pubmed: 23334245
Cancer Res. 2016 Sep 15;76(18):5326-36
pubmed: 27406829
J Exp Clin Cancer Res. 2019 Feb 18;38(1):87
pubmed: 30777100
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Mol Cancer. 2020 Aug 6;19(1):120
pubmed: 32762681
PLoS One. 2021 Mar 10;16(3):e0247293
pubmed: 33690665
Hum Immunol. 2005 Feb;66(2):146-54
pubmed: 15695000
Eur J Immunol. 2008 Dec;38(12):3474-86
pubmed: 19016529
J Immunol. 2013 Aug 1;191(3):1486-95
pubmed: 23817426
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Infect Dis. 2018 Nov 5;218(12):2006-2015
pubmed: 30099516
Hum Immunol. 2017 Mar;78(3):263-268
pubmed: 28088355

Auteurs

Haeyoun Choi (H)

Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

In-Cheol Baek (IC)

Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Soon A Park (SA)

Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Jae-Sung Park (JS)

Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Sin-Soo Jeun (SS)

Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Tai-Gyu Kim (TG)

Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Stephen Ahn (S)

Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Classifications MeSH